OPKO Reports First Patient Dosed in Phase 1/2a Trial in Acromegaly

10:17 AM EDT, 10/27/2026 (MT Newswires) -- OPKO Health's (OPK) OPKO Biologics unit said Tuesday the first participant has been dosed in a phase 1/2a trial of OPK-8801001 in acromegaly, a rare endocrine disorder caused by excess growth hormone. The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamic activity of OPK-8801001, the firm said. Price: 1.61, Change: -0.02, Percent Change: -1.23